Compound class:
Peptide or derivative
Comment: Blisibimod is a peptibody fusion containing four BAFF binding domains fused to a human Fc domain. By sequestering circulating BAFF ligand, it acts as a functional antagonist of BAFF interaction with the TACI receptor on B cells.
Peptide sequences and structural information for this peptide are available from its IMGT/mAb-DB entry. The peptide sequence for blisibimod is claimed in Amgen's patent WO2002092620 [5]. |
| No information available. |
Summary of Clinical Use  |
| Click here to link to the full list of blisibimod trials registered with ClinicalTrials.gov. |
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
